Trovagene Reports Second Quarter 2016 Financial Results and Accomplishments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Trovagene Reports Second Quarter 2016 Financial Results and Accomplishments
August 8, 2016 7:28 AM EDT
Cantor Fitzgerald upgraded TrovaGene (NASDAQ: TROV) from Hold to Buy with a price target of $7.00 (from $5.00).
For an analyst ratings summary and ratings history on TrovaGene click here. For more ratings news on TrovaGene click here.
Shares of TrovaGene closed at $5.20 yesterday.
...
More
August 5, 2016 10:04 AM EDT
Piper Jaffray maintained a Neutral rating on TrovaGene (NASDAQ: TROV), and cut the price target to $4.00 (from $5.00), following the company's 2Q earnings report. Trovagene reported revenue of $104K, below the Street' ~$270K. Total revenue consisted of royalty revenue of $48K as well as test revenue of $56K.
Analyst William... More
August 4, 2016 5:42 PM EDT
Trovagene (NASDAQ: TROV) reported Q2 EPS of ($0.34), $0.03 worse than the analyst estimate of ($0.31).
"I'm excited to be part of the Trovagene team," said Bill Welch, Chief Executive Officer of Trovagene. "We announced a number of significant clinical study results, publications, and new collaborations... More
